Results 11 to 20 of about 458,290 (296)

Immunohistochemistry of CA 125

open access: yesThe International Journal of Biological Markers, 1998
CA 125 is known as the marker that is most strongly associated with epithelial gynecological tumors. Compared to the number of publications on its use in serum assays, the application in immunohistochemistry is still limited.
M. Nap
doaj   +2 more sources

Correlation of CA-125 with different stages of endometriosis

open access: yesBangabandhu Sheikh Mujib Medical University Journal, 2018
This study was conducted to evaluate the association of serum cancer antigen (CA-125) level with the severity of pelvic endometriosis. Seventy diagnosed cases of pelvic endometriosis were included in this study.
Runa Laila   +3 more
doaj   +2 more sources

The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma.

open access: yesEuropean journal of gynaecological oncology, 1999
One hundred and twelve women with endometrial carcinoma were studied with serum sampling to determine preoperative and postoperative levels of CEA, CA 15-3, CA 19-9, TPA and CA 125. After surgical treatment 88 patients had stage I, 8 stage II, 14 stage III and 2 stage IV disease. Before treatment the sensitivity of CEA, CA 15-3, CA 19-9, TPA and CA 125
CHERCHI PL   +6 more
openaire   +4 more sources

Tumour Associated Antigens CA 15.3 and CA 125 in Ovarian Cancer

open access: yesThe International Journal of Biological Markers, 1991
CA 125 and CA 15.3 antigens were determined by enzyme immunoassay in 78 patients with ovarian cancer for a total of 540 determinations. The antigens were also investigated in sera from 100 women with other gynaecological diseases, 82 lung cancer patients
M. Lotzniker   +5 more
doaj   +3 more sources

CA-125 and CCL2 may indicate inflammation in peritoneal dialysis patients

open access: yes, 2021
Introduction: Progressive structural changes in the peritoneal membrane occur over the course of treatment in peritoneal dialysis (PD), resulting in an increase in cytokines such as CCL2 and structural changes in peritoneal membrane triggering an ...
Sylvia Dias Turani (12731553)   +6 more
core   +1 more source

Karakteristik Karsinoma Ovarium Pra-Menopause dengan Kadar CA 125 ≤200 U/mL di RSUP Dr. Hasan Sadikin Bandung dari Tahun 2019–2021

open access: yesObgynia, 2023
Tujuan: Mendeskripsikan karakteristik karsinoma ovarium pra-menopause dengan kadar CA 125 ≤ 200 U/mL di RSUP Dr. Hasan Sadikin Bandung dari tahun 2019 sampai 2021.
Yudi Mulyana Hidayat   +4 more
doaj   +1 more source

Struma Ovarii with Elevated Ca-125 Levels and Ascites Mimicking Advanced Ca Ovary [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2014
Struma ovarii is uncommon tumor of ovary which can mimic as advanced carcinoma of ovary. Thyroid tissue is relatively frequent constituent of mature ovarian teratoma.
Navin Kumar Sinha
doaj   +1 more source

Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors [PDF]

open access: yes, 2009
Background: The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and CA 72-4 in patients with ovarian borderline tumor (BOT).
Linda Hertlein   +17 more
core   +1 more source

Evaluating Lung Cancer with Tumor Markers: CEA, CA 19-9 and CA 125

open access: yesJournal of Contemporary Medicine, 2021
Aim: Lung cancer (LC) is a common and mortal malignancy. Tumor biomarkers are measurable biochemicals associated with cancer cells. Tumor markers cannot diagnose cancer; instead, they can be used as laboratory tests to support the diagnosis.
Aydın Balcı   +2 more
doaj   +1 more source

The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses [PDF]

open access: yes, 2011
Background: Cancer antigen 125 (CA125) is the best known single tumor marker for ovarian cancer (OC). We investigated whether the additional information of the human epididymis protein 4 (HE4) improves diagnostic accuracy.
Fuerst, Sophie   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy